Poland · Delayed Price · Currency is PLN Pure Biologics Statistics
Total Valuation
Pure Biologics has a market cap or net worth of PLN 26.16 million. The enterprise value is 40.65 million.
| Market Cap | 26.16M |
| Enterprise Value | 40.65M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pure Biologics has 4.08 million shares outstanding. The number of shares has increased by 19.84% in one year.
| Current Share Class | 4.08M |
| Shares Outstanding | 4.08M |
| Shares Change (YoY) | +19.84% |
| Shares Change (QoQ) | +3.33% |
| Owned by Insiders (%) | 12.74% |
| Owned by Institutions (%) | 4.94% |
| Float | 3.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.32 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -108.28% |
| Return on Invested Capital (ROIC) | -357.48% |
| Return on Capital Employed (ROCE) | 63.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.92M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.35% in the last 52 weeks. The beta is 1.04, so Pure Biologics's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -65.35% |
| 50-Day Moving Average | 6.58 |
| 200-Day Moving Average | 9.37 |
| Relative Strength Index (RSI) | 48.75 |
| Average Volume (20 Days) | 42,992 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -41,000 |
| Operating Income | -11.53M |
| Pretax Income | -13.03M |
| Net Income | -17.53M |
| EBITDA | -11.39M |
| EBIT | -11.53M |
| Earnings Per Share (EPS) | -4.52 |
Balance Sheet
The company has 295,000 in cash and 14.78 million in debt, giving a net cash position of -14.49 million or -3.55 per share.
| Cash & Cash Equivalents | 295,000 |
| Total Debt | 14.78M |
| Net Cash | -14.49M |
| Net Cash Per Share | -3.55 |
| Equity (Book Value) | -18.17M |
| Book Value Per Share | -4.45 |
| Working Capital | -18.20M |
Cash Flow
| Operating Cash Flow | -6.60M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pure Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.84% |
| Shareholder Yield | n/a |
| Earnings Yield | -67.00% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |